Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)

Relmada Therapeutics (RLMD) has reported Research & Development for 13 consecutive years, with $8.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 32.33% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $23.0 million (down 48.65% YoY), while the FY2025 annual figure was $26.9 million, down 41.79% from the prior year.
• Research & Development was little changed at $8.1 million in Q1 2026 per RLMD's latest filing, from $8.1 million in the prior quarter.
• Across five years, Research & Development topped out at $30.9 million in Q2 2022 and bottomed at $2.8 million in Q2 2025.
• Historically, Research & Development has averaged $14.7 million across 5 years, with a median of $12.0 million in 2025.
• Annual changes were most pronounced in 2022 — Research & Development jumped 78.38% — and 2025, when it sank 73.7%.
• Relmada Therapeutics' Research & Development stood at $26.9 million in 2022, then slumped by 45.1% to $14.8 million in 2023, then dropped by 25.43% to $11.0 million in 2024, then fell by 26.61% to $8.1 million in 2025, then advanced by 0.19% to $8.1 million in 2026.
• Business Quant data shows RLMD's Research & Development at $8.1 million in Q1 2026, $8.1 million in Q4 2025, and $4.0 million in Q3 2025.